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According to the Centers for Disease Control and Prevention, 
breast cancer susceptibility gene (BRCA) mutation testing is 
one of the few genetic applications with evidence of validity 
and utility that supports its implementation into practice.1 
However, such recommendations do not take into account 
the economic perspective. Furthermore, the available assess-
ment tools for evaluating genetic tests, such as the Evaluation 
of Genomic Applications in Practice and Prevention model, 
do not provide adequate information on the economic 
aspects.2 Moreover, there has been little research on the 
effectiveness or return on investment of implementation and 
dissemination research.3–5 Economic evaluation may be use-
ful in this regard because it analyzes the delivery of a specific 
genomic test under real-life conditions within a genomic 
health-care program that has the underlying objective of 
maximizing the health of the population with the available 
resources.6
Inheritance of a dominant mutation in one of two breast/
ovarian cancer susceptibility genes (BRCA1 and BRCA2) is 
responsible for 2–7% of breast cancers and 10–15% of ovar-
ian cancers.7–9 Implementation of prevention programs would 
reduce the burden of such inherited diseases, and in some 
countries public health genomics policies have already been 
formulated and genetic interventions included in public health 
strategies for preventive medicine. For example, in Italy, the 
2014–2018 National Prevention Plan contemplates the devel-
opment of regional BRCA genetic testing programs because 
such programs can increase awareness of hereditary cancer 
risk in the population and reduce incidence and mortality of 
BRCA-related cancers.10 However, it is not clear which BRCA 
genetic programs are the most efficient and therefore which 
should be implemented. Can population-based screening for 
BRCA mutations be considered good value for the money, and 
under what conditions? Does limiting BRCA testing to at-risk 
individuals yield the most health gains at an acceptable cost? Or 
could it be more cost-effective to begin testing individuals with 
breast or ovarian cancers to find probands and to follow up with 
cascade screening among relatives?
This study has two purposes. The first is to identify the BRCA 
genetic testing programs whose cost-effectiveness has been 
analyzed in published economic evaluations. The second is 
to provide an overview of which BRCA testing programs are 
potentially ready for implementation on the basis of their cost-
effectiveness, structure, and main assumptions, together with 
a discussion of the difficulties of transferring context-specific 
tools such as economic evaluations to other settings.11
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Purpose: There is considerable evidence regarding the efficacy and 
effectiveness of BRCA genetic testing programs, but whether they 
represent good use of financial resources is not clear. Therefore, we 
aimed to identify the main health-care programs for BRCA testing 
and to evaluate their cost-effectiveness.
Methods: We performed a systematic review of full economic eval-
uations of health-care programs involving BRCA testing.
Results: Nine economic evaluations were included, and four main 
categories of BRCA testing programs were identified: (i) population-
based genetic screening of individuals without cancer, either com-
prehensive or targeted based on ancestry; (ii) family history (FH)-
based genetic screening, i.e., testing individuals without cancer but 
with FH suggestive of BRCA mutation; (iii) familial mutation (FM)-
based genetic screening, i.e., testing individuals without cancer but 
with known familial BRCA mutation; and (iv) cancer-based genetic 
screening, i.e., testing individuals with BRCA-related cancers.
Conclusions: Currently BRCA1/2 population-based screening rep-
resents good value for the money among Ashkenazi Jews only. FH-
based screening is potentially very cost-effective, although further 
studies that include costs of identifying high-risk women are needed. 
There is no evidence of cost-effectiveness for BRCA screening of all 
newly diagnosed cases of breast/ovarian cancers followed by cascade 
testing of relatives, but programs that include tools for identifying 
affected women at higher risk for inherited forms are promising. 
Cost-effectiveness is highly sensitive to the cost of BRCA1/2 testing.
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MAteRiALs And MetHOds
This review was conducted according to the Center for Reviews 
and Dissemination guidance on undertaking systematic 
reviews of economic evaluations12 and the Cochrane Handbook 
for systematic reviews of interventions.13
inclusion criteria
Broad inclusion criteria were used to encompass all economic 
evaluations of BRCA testing programs in the literature. A BRCA 
testing program was defined as any type of health intervention 
that includes BRCA testing in a target population with the pur-
pose of reducing the risk of breast and ovarian cancer (initial 
and second primary), for example, by prophylactic surgery or 
intense surveillance of mutation-positive patients. According 
to this definition, a BRCA testing program should consist of 
the following components: a target population to test, genetic 
counseling, genetic testing to identify mutation carriers, and 
specific health-care pathways for individuals with and without 
genetic mutations. In particular, studies considered suitable for 
inclusion should evaluate the costs and benefits of a BRCA test-
ing program, as well as the consequent health-care pathways 
specified.
We included studies that used standard full economic 
evaluation designs such as cost-effectiveness analysis (CEA), 
cost-utility analysis (CUA), cost-benefit analysis, or cost-
minimization analysis.6 All health-related and cancer-related 
outcomes were included. It was anticipated that the major-
ity of studies would measure the number of cases of cancer 
detected, life-years gained (LYG), or quality-adjusted life-
years (QALYs). Studies were included regardless of the per-
spective of the evaluation (health-care system or a broad 
societal perspective).
search strategy
Relevant studies (from inception to December 2014) were 
searched using the following databases: Medline, Embase, 
Scopus, the Health Economic Evaluations Database (HEED), 
the CEA Registry, the Economics Literature Index (EconLit), 
the Health Technology Assessment (HTA) Database, and 
the National Health Service Economic Evaluation Database 
(NHS EED). The literature search was rerun in February 
2015 to identify any relevant studies published since the 
original search date. Two investigators conducted the lit-
erature search independently, to enhance sensitivity. The 
search terms were developed in relation to the intervention, 
outcomes, and designs of the studies: “BRCA1 OR BRCA2” 
AND “genetic* OR gene OR genom*” AND “economic* OR 
cost-effectiveness OR cost-utility OR cost-benefit OR cost-
minimization OR cost*”. The strings were adjusted for each 
database while maintaining a common overall architecture. 
The search strategy for Medline and Embase included both 
MeSH terms and free texts of the primary search terms. The 
reference lists of retrieved articles were also searched to 
identify potentially relevant studies.
selection of studies
Two reviewers selected relevant studies, removed duplicates, 
and screened titles and abstracts of the returned citations. 
Studies that clearly did not meet the inclusion criteria were 
excluded. Full texts of potentially relevant articles were retrieved 
and independently examined by two pairs of reviewers to deter-
mine the eligibility of papers. Disagreements were resolved 
through discussion and reasons for exclusion recorded.
data extraction and quality assessment
Data were collected from the included studies by two reviewers 
independently and checked by a third reviewer. Data extrac-
tion focused on key methodological features (type of economic 
evaluation, analytical approach, outcome measures, study per-
spective, collection of cost and effectiveness data, time horizon, 
discounting, sensitivity analyses), key characteristics of the 
intervention (setting, target population, gene and clinical con-
dition, scope of testing), and health-care pathways. Additional 
information, such as authors, journal, funding declaration, and 
year of publication, was also extracted.
Quality was assessed using two tools: the BMJ checklist14 and 
the Quality of Health Economic Studies (QHES) list.15 The for-
mer gives a qualitative assessment of quality of economic evalu-
ations, and the second is quantitative, enabling us to integrate 
both approaches. The BMJ tool is more detailed than the QHES 
instrument (35 vs. 16 items); each item on the BMJ checklist 
reflects a specific aspect of methodological process, whereas 
the QHES list includes double-barreled items (multiple 
Figure 1 Flow diagram for selection of full economic evaluations of 
BRCA1/2 testing programs. (Adapted from ref. 30)
Records excluded after reading 
title/abstract  
(n = 678) 
Full-text articles assessed for
eligibility (n = 29)
Full-text articles excluded for not 
satisfying inclusion criteria (n = 21): 
- 1 is a partial economic evaluation; 
- 13 only evaluate costs and benefits 
of the health-care pathways after 
BRCA testing; 
- 7 are not full economic evaluations. 
Studies included in the systematic
review (n = 8)
Studies included after updated
literature search
(n = 1)
Records after duplicates removed
(n = 707)
Records identified though database searching
(MEDLINE, EMBASE, Scopus, HEED, CEAR,
EconLit, HTA database, NHS EED)
(n = 1,096)
Records screened
(n = 707)
Studies included in the systematic
review (n = 9)
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methodological aspects under the same item). The BMJ tool 
specifically identifies every potential methodological error and 
produces a descriptive critical assessment, whereas the QHES 
tool gives an overall score for each included study.
Three reviewers performed the quality assessment of studies 
using both checklists independently. Cohen’s kappa was calcu-
lated to quantify the level of agreement among reviewers, and 
disagreements were resolved by peer discussion.16
Because quality assessment primarily reflects the extent to 
which the studies adhere to standard methods, an effort was 
made to evaluate the plausibility of the basic assumptions of 
each study to better appraise the quality of its findings.
data synthesis
Owing to substantial heterogeneity among studies, a meta-analy-
sis was not possible. A narrative synthesis of the identified stud-
ies was performed to summarize the key features of the included 
studies and to compare study questions, interventions, meth-
ods, and results. In both CEA and CUA, the main result is usu-
ally expressed as an incremental cost-effectiveness ratio (ICER), 
defined as the ratio that relates difference in costs to difference 
in outcomes between two alternative interventions. Policymakers 
may decide if an intervention is an efficient use of resources 
using a threshold of maximally acceptable cost per unit of out-
come. Because there is no universally accepted ICER threshold, 
we adopted the most common cost-effectiveness thresholds used 
in the United States ($50,000–100,000/QALY or LYG)17,18 and the 
United Kingdom (£20,000–30,000/QALY or LYG).19 The ICERs 
provided by the CEA registry, maintained by Tufts Medical 
Center, were also extracted.20 In the Tufts database, all the original 
ICERs are converted into US dollars and adjusted for inflation.
ResULts
The electronic search identified 707 studies. Title and abstract 
screening reduced this number to 29 potential studies, which 
were retrieved for full text review. After full text review, a 
further 21 studies were excluded, leaving 8 studies.20–28 An 
additional relevant study was identified in the updated litera-
ture search.29 Therefore, a total of nine economic evaluations 
were included in the systematic review, all published in peer-
reviewed journals. A flow diagram of the selection of studies is 
shown in Figure 1, and the list of studies excluded at the full 
text review stage, including reasons for exclusion, is available 
on request.
Characteristics of studies
The key characteristics of the included studies are reported in 
Table 1. Three studies used CEA,21,22,24 four used CUA,23,25,27,29 
and two used both CEA and CUA.26,28 All the most recent 
studies, published from 2009 until 2015, included a CUA.25–
29 Six economic evaluations were performed in the United 
States,21,23,25–28 and three were performed in Europe (United 
Kingdom, Spain, and Norway).22,24,29 All but one study evalu-
ated BRCA testing programs for both BRCA1 and BRCA2 
genes; the exception included only a BRCA1 test.22 Six eco-
nomic evaluations considered both breast and ovarian cancers, 
two referred only to breast cancer,22,24 and one study related 
only to ovarian cancer.25
Nearly all studies were based on hypothetical BRCA 
genetic screening programs and used assumptions and 
probabilities extracted by other studies to model the impact 
of genetic testing.21,24–28 Two derived benefits from inter-
nal databases.22,23 Only one study performed a trial-based 
table 1 General characteristics of full economic evaluations of BRCA1/2 testing programs
First author, 
country, and year of 
publication
Clinical 
condition
Gene(s) 
mutation 
tested
type(s) of 
economic 
evaluation
Methodological issues
Model of 
analysis
Quality 
score  
(QHes list)
time 
horizon Perspective
Baseline 
year of 
evaluation discounting
Manchanda, UK, 2015 Breast and 
ovarian cancer
BRCA1, 
BRCA2
CUA NS NS 2010 0.035 (costs and 
benefits)
Decision 
analysis model
96/100
Kwon, USA, 2010 Breast and 
ovarian cancer
BRCA1, 
BRCA2
CEA  
and CUA
Lifetime Societal 2009 0.03 (costs and 
benefits)
Markov model 79/100
Kwon, USA, 2009 Breast and 
ovarian cancer
BRCA1, 
BRCA2
CEA  
and CUA
Lifetime Societal 2008 0.03 (costs and 
benefits)
Markov model 92/100
Rubinstein, USA, 2009 Ovarian cancer BRCA1, 
BRCA2
CUA Lifetime NS 2007 0.03 (costs) Decision 
analysis model
71/100
Holland, USA, 2009 Breast and 
ovarian cancer
BRCA1, 
BRCA2
CUA 70 years Societal 2006 0.03 (costs and 
benefits)
Markov model 88/100
Balmana, Spain, 2004 Breast cancer BRCA1, 
BRCA2
CEA Lifetime NS NS 0.05 (costs) Trial-based 
analysisa
74/100
Tengs and Berry, USA, 
2000
Breast and 
ovarian cancer
BRCA1, 
BRCA2
CUA Lifetime Societal 1998 0.03 (costs and 
benefits)
Markov model 70/100
Heimdal, Norway, 1999 Breast cancer BRCA1 CEA 25 years NS 1999 NS NS 37/100
Grann, USA, 1999 Breast and 
ovarian cancer
BRCA1, 
BRCA2
CEA 50 years Societal 1995 0.03 (costs) Markov model 70/100
CEA, cost-effectiveness analysis; CUA, cost-utility analysis; NS, not specified; QHES, Quality of Health Economic Studies.
aIn a cohort of 143 high-risk families.
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analysis and extrapolated the outcomes of that experimental 
study to obtain long-term cost-utility estimates.22
The time horizon was lifetime in five studies,23,24,26–28 between 
25 and 70 years in three studies,21,22,27 and in one case it was not 
specified.23 However, the time horizon in all studies was long 
enough to reflect differences in costs and outcomes. The most 
frequent viewpoint declared by the authors was the societal 
perspective,21,23,25,26,28 but in four studies the perspective was not 
stated clearly.22,24,27,29
Quality assessment and basic assumptions
The main criticism of the study design is that the viewpoint of 
analysis was stated in only five of the nine economic evalua-
tions21,23,25,26,28; the perspective declared by the authors was 
consistent with the costs included in the analysis in only two 
evaluations.25,26 By contrast, all other aspects of the study design 
were fulfilled in almost all economic evaluations (Table 2). 
Concerning data collection, there were several issues. Although 
the clinical effectiveness of the interventions was stated in the 
table 2 Quality assessment of full economic evaluations of BRCA1/2 testing programs according to the BMJ checklist
Quality item
number 
of studies 
complying nA
Study design
The research question is stated 9/9 —
The economic importance of the research question is stated 8/9 —
The viewpoint(s) of the analysis is clearly stated and justified 5/9 —
The rationale for choosing alternative programs or interventions compared is stated 9/9 —
The alternatives being compared are clearly described 9/9 —
The form of economic evaluation used is stated 9/9 —
The choice of form of economic evaluation is justified in relation to the questions addressed 6/9 —
Data collection
The source(s) of effectiveness estimates used is stated 8/9 —
Details of the design and results of effectiveness study are given (if based on a single study) — 8/9
Details of the methods of synthesis or meta-analysis of estimates are given (if based on a synthesis of a number of  
effectiveness studies)
— 1/9
The primary outcome measure(s) for the economic evaluation is clearly stated 9/9 —
Methods to value benefits are stated 2/9 3/9
Details of the subjects from whom valuations were obtained are given 1/9 3/9
Productivity changes (if included) are reported separately — 9/9
The relevance of productivity changes to the study question is discussed — 9/9
Quantities of resource use are reported separately from their unit costs 9/9 —
Methods for the estimation of quantities and unit costs are described 9/9 —
Currency and price data are recorded 8/9 —
Details of currency of price adjustments for inflation or currency conversion are given — —
Details of any model used are given 8/9 —
The choice of model used and the key parameters on which it is based are justified 8/9 —
Analysis and interpretation of results
Time horizon of costs and benefits is stated 7/9 —
The discount rate(s) is stated 8/9 —
The choice of discount rate(s) is justified 6/9 —
An explanation is given if costs and benefits are not discounted — 9/9
Details of statistical tests and confidence intervals are given for stochastic data — 9/9
The approach to sensitivity analysis is given 3/9 —
The choice of variables for sensitivity analysis is justified 3/9 —
The ranges over which the variables are varied are justified 3/9 —
Relevant alternatives are compared 9/9 —
Incremental analysis is reported 5/9 —
Major outcomes are presented in a disaggregated as well as aggregated form 7/9 —
The answer to the study question is given 9/9 —
Conclusions follow from the data reported 9/9 —
Conclusions are accompanied by the appropriate caveats 5/9 —
NA, not appropriate.
 Volume 18  |  Number 12  |  December 2016  |  GenetiCs in MediCine
1175
BRCA genetic testing programs: a systematic review of economic evaluations  |  D’ANDREA et al SyStematic Review
majority of studies, none gave details of how the effectiveness 
data were combined from several sources (Table 2). Health 
benefits were valued in six studies in which the main effect was 
on the quality of life, whereas in the remainder the health mea-
sures were LYG or cancer detected.21,22,24 Among studies using 
CUA, details of the methods used (e.g., time trade-off, standard 
gamble, contingent valuation) were given only in two stud-
ies,25,29 and the subjects from whom valuations were obtained 
(e.g., patients, members of the general public, health-care 
professionals) were specified only in one study.25 All studies 
made an appropriate measurement of costs, but none consid-
ered price adjustments for inflation or currency conversion 
(Table 2). Regarding the analysis and interpretation of results, 
the main criticism is how sensitivity analyses were used because 
only three economic evaluations tested results using two-way 
(or more complex) analyses.25,26,29 Another critical point is the 
lack of incremental analysis (Table 2). In three economic evalu-
ations, the programs described were only compared with the 
situation where no testing was performed21–23; in another case, 
there was no incremental analysis at all.25
In general, studies were well conducted and the average qual-
ity was good. The median QHES score was 74, with a range 
of 37–96 (Table 1). There has been a gradual increase in the 
quality of studies over time, and those economic evaluations of 
higher quality were published in the past 5 years of the study 
period (from 2009 to 2014) (Table 1). The mean scores (±SD) 
awarded by the three reviewers for the assessment set were 73.8 
(±19.2), 76.0 (±18.6), and 74.4 (±17.1) (P value for ANOVA = 
0.966). The agreement for dichotomous scoring was high (κ = 
0.8). The three reviewers scored 85% of the studies in the test 
set within 10 points, showing very good agreement. The criteria 
that required the most objective response (disclosing funding 
source and conduct of sensitivity analyses) received the highest 
level of agreement. The criteria with the lowest agreement lev-
els were the discussion of magnitude and direction of potential 
biases and the inclusion of short-term, long-term, and negative 
outcomes.
Basic assumptions and main model inputs have been extracted 
to assess their impact on the results (see Supplementary 
Table S1 online). The main critical issues are the entity of risk 
reduction after preventive interventions, the compliance of 
patients with prophylactic surgery, the uptake of BRCA testing 
among at-risk relatives of index cases, and the costs of genetic 
testing. Risk reductions for breast and ovarian cancer after pre-
ventive interventions were higher in the most recent studies,25–29 
because they were based on updated guidelines. This means 
that the cost-effectiveness ratios resulting from less recent 
studies, in which risk reductions were lower, may be overes-
timated.21,24 Patient compliance with prophylactic surgery was 
assumed to be 100% in some studies,21,22,24,28 and only one study 
tested patient compliance in the sensitivity analysis, showing a 
moderate impact on the results.28 The level of uptake of BRCA 
testing among relatives of index cases was specified only in two 
studies and varied between 5026 and 100%,22 but it was not tested 
in the sensitivity analysis. However, the 50% rate of compliance 
with genetic testing among relatives provided some evidence of 
cost-effectiveness.26 Concerning BRCA1/2 genetic testing costs, 
substantial differences exist between full sequence analysis of 
BRCA genes23–26,28 and tests of specific BRCA mutations.21,22,27,29 
These specific tests are far less expensive, but because they are 
context-specific the results of their studies are difficult to gen-
eralize to other settings.
evidence of cost-effectiveness
To aid interpretation, four main categories of the BRCA test-
ing program were identified on the basis of target populations: 
(i) population-based genetic screening of individuals without 
cancer, either comprehensive or targeted based on ancestry 
or ethnicity; (ii) family history (FH)-based genetic screening, 
i.e., testing unaffected individuals with FH suggestive of BRCA 
mutation but in whom a familial mutation (FM) has not been 
identified; (iii) FM-based genetic screening, i.e., testing unaf-
fected individuals with a known familial mutation; and (iv) 
cancer-based genetic screening, i.e., testing individuals with 
BRCA-related cancers to prevent the occurrence of further pri-
mary cancers (Table 3).
Population-based genetic screening. The broadest approach 
involves population-based genetic screening of individuals 
without cancer, either comprehensive or subpopulations. Three 
studies focused on a specific ethnic group, the Ashkenazi 
Jewish (AJ) communities in Israel, United States, and United 
Kingdom,21,27,29 and one program targeted the general 
population.23 Studies targeted at the AJ community included, 
as a routine genetic test, the “BRCA founder-mutation 
test,”21,27,29 which tests only three specific mutations in BRCA 
(BRCA1*185delAG, BRCA1*5382insC, and BRCA2*6174delT); 
these mutations account for ∼95% of detectable BRCA 
mutations in dominantly inherited early-onset breast and 
ovarian cancer in families of AJ ancestry.31–33
In the first study, two strategies were compared.29 In the first 
of these, BRCA genetic testing was offered to all women belong-
ing to the AJ community. For this ethnicity, the probability of 
having a mutation was assumed to be 2.45% by the authors. The 
second strategy was consistent with current recommendations: 
genetic testing was offered only to women in the AJ community 
with a definite risk, which was determined from information 
on familial and personal history (FH-based screening). In this 
subpopulation, the prevalence of BRCA mutation was higher 
than in the previous target group (9.38%). In both strategies, 
those AJ women with positive results in the BRCA genetic test 
(carriers) were encouraged to undertake specific preventive 
health-care pathways, which may include prophylactic surgery 
to reduce ovarian and breast cancer risk or, as an alternative to 
preventive mastectomy, early detection of breast cancer by sur-
veillance with magnetic resonance imaging and mammography 
each year, followed by curative mastectomy. For both strategies, 
the authors assumed that slightly more than 50% of carriers 
would decide to undergo preventive surgery or surveillance. 
The population-based approach was cost-saving compared 
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with FH-based screening in AJ women, but no comparison was 
made with a no-testing strategy.29
The second study focused on ovarian cancer risk only in AJ 
women, and a comparison between population-based genetic 
screening and no testing was conducted.27 The preventive inter-
vention in BRCA carriers was bilateral salpingo-oophorectomy 
(BSO), assuming a carrier compliance with surgery of 50%. 
Also, in this case, favorable conclusions were reached regarding 
the cost-effectiveness of the BRCA testing ($10,309/LYG and 
$8,300/QALY).27
In the third study, four hypothetical scenarios were compared 
with no testing.21 In all scenarios, the founder mutations were 
tested in AJ women, assuming a BRCA mutation prevalence of 
2.5%. Four types of preventive interventions were analyzed. In 
the first, all carriers underwent combined surgery (mastectomy 
and oophorectomy). In the second and third scenarios, carriers 
were encouraged to undergo prophylactic bilateral mastectomy 
or bilateral oophorectomy, respectively. In the last, only sur-
veillance was offered to them. In all scenarios carrier compli-
ance was assumed to be 100%, and this has not been assessed 
by sensitivity analysis. Taking into account the current thresh-
olds, the analysis suggested that screening AJ women for BRCA 
mutations would be cost-effective only if those testing positive 
underwent combined surgery ($20,717/LYG), or mastectomy 
($29,717/LYG).21 The authors considered bilateral oophorec-
tomy to reduce the risk of ovarian cancer to 45%. Currently, the 
recommended prophylactic surgery for inherited BRCA can-
cers is BSO, with a risk reduction of 96%; this was considered in 
the previous two studies discussed here.27,29
Tengs and Berry23 considered BRCA testing screening of the 
general population (0.02–0.06% probability of carrying a BRCA 
mutation) with an option for identified BRCA carriers to decide 
whether to undergo prophylactic surgery. The results clearly 
suggest that population-based screening is too expensive to be 
justified by the health gains achieved.
FH-based genetic screening. In an FH-based screening 
approach, the information is obtained by interviewing 
individuals about their personal and familial history; women 
who may have an increased risk of hereditary breast and 
ovarian cancer are offered genetic testing.34 Two economic 
evaluations analyzed this approach.23,25 The target population 
was unaffected women with FH suggestive of a BRCA mutation 
and with an unknown mutation in their families (Table 3).
The first study included target populations of women who 
differed in the strength of their FH of breast or ovarian cancer, 
with probabilities of identifying a BRCA mutation being 5, 10, 
or 25–50%.23 Prophylactic surgery was offered to BRCA carriers 
in all programs. Incremental analysis was not performed, and 
all strategies were compared with a no-testing situation. The 
results showed that testing unaffected women with greater than 
10% probability of a BRCA mutation was very cost-effective 
($3,500–15,000/QALY).23
In the second study, the target population comprised 35-year-
old women, including women at high risk based on their FH 
and those who were concerned they might carry a BRCA 
mutation. In both cases the probability of identifying a BRCA 
gene mutation was 10% and no FM had been characterized.25 
Prophylactic surgery was offered to BRCA mutation-positive 
women. This strategy was cost-effective ($5,000/QALY) when 
compared with no intervention. Using data from a sensitivity 
analysis, the authors established that the “test strategy” is cost-
effective even when the pretest probability of mutation was less 
than 10%, as long as a negative mutation result leads to a utility 
gain for at-risk women.25
FM-based genetic screening. The third potential screening 
approach is FM-based genetic screening, in which genetic tests 
are performed on the close relatives of previously identified 
index cases. Three economic evaluations analyzed this approach 
(Table 3).22,24,26
In the first study, only one of the two BRCA programs ana-
lyzed met our inclusion criteria because the other program did 
not include genetic analysis to identify women with cancer-
predisposing mutations.22 In the included program, a BRCA1 
genetic test was offered by physicians to all women with breast 
and/or ovarian cancer, without pretest counseling. If a BRCA1 
mutation was found (index case), then the genetic test was per-
formed on relatives (cascade screening). The preventive inter-
vention for positive relatives was surveillance. This program, 
compared with no intervention, was cost-effective both in 
terms of life-years saved (€832/LYG) and number of inherited 
breast cancer diagnoses (€18,720 per cancer detected).22
The second study evaluated a BRCA genetic program for 
inherited breast cancer carried out in a Spanish hospital.24 
A  dedicated hospital unit performed genetic counseling to 
identify women at high risk for breast cancer. After counseling, 
the index cases of families who met the criteria for hereditary 
breast cancer were tested; if a BRCA mutation was found, then 
all close relatives were encouraged to undergo genetic analysis. 
BRCA carriers and females from high-risk families (without an 
identified mutation in their families) received intensive sur-
veillance until age 80 or early onset of breast cancer. Women 
who tested negative followed the standard population breast 
cancer screening program. This program was shown to be cost-
effective (€4,294/LYG) compared with no screening. The cost-
effectiveness analysis was focused only on breast cancer early 
detection with surveillance; neither the impact on costs nor the 
reduction of breast and ovarian cancer associated with preven-
tive surgery was considered.24
The third study targeted women with ovarian cancer.26 Four 
strategies were considered: no testing; testing at-risk women 
for inherited ovarian cancer identified using the Society of 
Gynecologic Oncologists criteria (pretest probability 10%); 
testing only women with invasive serous cancer; and testing 
all women with ovarian cancer. If the women tested positive, 
then their first-degree relatives were tested and risk-reducing 
interventions were performed. The only program shown to be 
cost-effective according to current thresholds was that involv-
ing testing of women with cancer ($32,018/LYG and $32,670/
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QALY) after performing a risk assessment based on the Society 
of Gynecologic Oncologists criteria.26
Cancer-based genetic screening. In the last screening 
approach, genetic tests are offered to individuals with a cancer 
diagnosis for the purpose of diagnosing inherited cancer 
predisposition. Only one economic evaluation analyzed this 
approach (Table 3).28 This study estimated costs and benefits 
of different BRCA testing programs in women younger than 
50 years old with breast cancer, regardless of their FH and 
ethnicity.28 Several testing strategies were considered according 
to type of breast cancer (medullary, triple-negative) and age of 
onset (women younger than 40 or 50 years old). In the baseline 
analysis, the authors assumed that all carriers would choose 
to undergo surgery, whereas compliance levels varied in the 
sensitivity analysis, ranging up to 20% for mastectomy and 55% 
for BSO. Cascade testing among relatives was not included in 
the model. The results showed that testing women younger than 
40 years old with any type of breast cancer and testing women 
younger than 50 years old with triple-negative breast cancer 
were both cost-effective if the preventive treatment for carriers 
was prophylactic surgery (ipsilateral and/or contralateral 
mastectomy and BSO) ($7,070 and $8,027/LYG and $8,085 and 
$9,094/QALY, respectively).28
disCUssiOn
The main challenge in conducting a systematic review of eco-
nomic evaluations derives from their high degree of hetero-
geneity, meaning that results cannot be pooled across studies 
by meta-analysis or other quantitative synthesis methods.12,13 
Consequently, the majority of such reviews have presented 
the results obtained in a narrative format.11 In the case of 
genetic testing, previously published systematic reviews 
have focused principally on assessing the methodological 
quality of economic evaluations, or simply on identifying 
which genetic testing programs were supported by eco-
nomic evidence; therefore, they were able to include a wide 
range of genetic tests.35–39 The outcome of these systematic 
reviews was that most genetic testing programs result in bet-
ter health care, but usually at a higher cost, and save money 
only in a small minority of cases.18,40 These findings are 
similar to those from other health-care areas, where it was 
estimated that only a low percentage of preventive measures 
and treatments for existing conditions are cost-saving.41,42 
Relatively few systematic reviews have focused on a specific 
genetic test and only one analyzed BRCA1/2 testing, with the 
main purpose of identifying available economic evidence to 
support the use of a specific laboratory method for detect-
ing BRCA mutations in UK genetic services.43 By contrast, 
our systematic review used a qualitative approach to identify 
genetic health-care programs for BRCA-related diseases that 
are ready for implementation in clinical practice based on 
the cost-effectiveness evidence. Four categories of genetic 
screening programs were identified: population-based, 
FH-based, FM-based, and cancer-based genetic screening.
Estimates of cost-effectiveness of population-based BRCA1/2 
testing indicate that this strategy is currently too expensive. It 
has been calculated that even if every woman with a detected 
mutation underwent bilateral mastectomy and salpingo-
oophorectomy, universal screening would still cost in excess of 
$1 million per QALY gained.44 By contrast, population-based 
screening targeted at Ashkenazi Jewish women seems to be rea-
sonable and cost-effective if carriers undergo prophylactic sur-
gery.21,27,29 The difference is explained not only by the prevalence 
of mutations (AJ, 2.5%; general population, 0.002–0.006%) but 
also by the price of the test, because testing a woman from the 
general population costs at least five times more than testing a 
AJ woman. Despite its cost-effectiveness, the current guidelines 
do not explicitly recommend population-based screening of AJ 
women, and AJ heritage is considered only one of several risk 
factors that may increase the total risk of having a deleterious 
BRCA mutation.45,46
In FH-based screening, the unit of analysis is not the individ-
ual but the entire family. Accordingly, three steps should be fol-
lowed: identify high-risk individuals through an assessment of 
personal and FH, test the affected family member to identify a 
significant FM, and in the case of a positive test result, perform 
direct gene testing on apparently unaffected family members. 
The economic evaluations of FH-based screening showed two 
important deficiencies: none discussed how to select high-risk 
women in the general population, thereby failing to detail the 
related costs, and none modeled cascade screening among rela-
tives of carriers following the detection of index cases. For these 
reasons, the cost-effectiveness ratios calculated in these stud-
ies should be considered of limited utility; more information is 
needed for a complete evaluation. Despite this, the possibility 
that this screening approach is cost-effective appears very high 
if the probability of mutation in the at-risk population is 10% 
or higher.
The category of FM-based genetic screening detects index 
cases by directly testing women with breast and/or ovarian 
cancers. In the event that a mutation is identified in index sub-
jects, genetic analysis is performed on unaffected relatives. All 
three economic evaluations that analyzed this approach showed 
some evidence of cost-effectiveness. Problems such as the lack 
of a defined pretest probability of affected women, the deci-
sion to study only two BRCA1 mutations, the unknown per-
centage of at-risk relatives of index cases who elect to undergo 
testing, and the unrealistically high expected compliance with 
preventive strategies among carriers limit the amount of use-
ful information gathered by testing all women with breast and/
or ovarian cancers that can be drawn from the first study.22 
Assumptions seem to be more robust in the second and third 
studies, in which genetic tests to identify index cases were 
offered to women with breast and/or ovarian cancers at age 30 
and to women with ovarian cancer younger than 50 years.24,26 
If a mutation was found, then unaffected relatives were tested 
and prophylactic interventions were offered to them. In both 
studies, the cost-effective strategies were those in which genetic 
tests were offered to affected women at risk for inherited breast/
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ovarian cancer according to personal and familial criteria.24,26 
Currently, there is no evidence for testing all individuals with 
BRCA-related cancers to identify index cases regardless of their 
clinical and familial histories.
The only study included in the last category, i.e., cancer-based 
genetic screening, proposed genetic screening of several popu-
lations of women with breast cancer, stratified by subtypes and 
age of onset, with the purpose of preventing the occurrence of 
further primary cancers, without considering cascade testing of 
relatives.28 This approach was cost-effective only under particu-
lar conditions.28
Our survey of the literature found only nine full economic 
evaluations of BRCA genetic testing. Most of these were of 
acceptable quality, although some methodological limitations 
should be mentioned. For example, the included costs were fre-
quently inadequate. Thus, although the societal perspective is 
the most appropriate for the analysis of health-care programs 
and five economic evaluations adopted this perspective, none 
of the authors included social costs. The following other limita-
tions are worth highlighting: (i) few details were reported on 
data abstraction for the base-case estimates, (ii) none of the 
evaluations considered price adjustments for inflation or cur-
rency conversion, and (iii) only three economic evaluations 
performed appropriate sensitivity analysis (two-way or more 
complex). Finally, the evaluations were conducted in a limited 
range of countries (United States, United Kingdom, Norway, 
and Spain), and whether the results are generally applicable 
was not addressed in the included studies. A previous review of 
studies on the cost-effectiveness of BRCA genetic testing identi-
fied similar limitations, pointing out the considerable variety in 
methodologies and hence problems of transparency, compara-
bility, and generalizability.43
In conclusion, the results of this systematic review indicate 
that, although BRCA1/2 population-based screening is cur-
rently an inefficient use of health-care resources, population-
based screening of the AJ community appears to be a good 
value for the money. Furthermore, it is highly likely that 
FH-based screening will prove cost-effective, although further 
economic evaluations that include the costs of identifying high-
risk women are needed to fully justify this conclusion. This 
point is crucial because counseling strategies to detect at-risk 
individuals could involve primary-care physicians, and cur-
rently physicians seem to be not yet adequately prepared about 
hereditary breast cancer and BRCA1/2 testing.47,48 Finally, in 
contrast to genetic testing for hereditary colorectal cancer (i.e., 
Lynch syndrome),49–51 there is no evidence for the cost-effec-
tiveness of screening for BRCA1/2 of newly diagnosed cases of 
breast and ovarian cancers, followed by cascade testing of rela-
tives. However, cancer-based genetic screening programs for 
BRCA1/2 that includes tools for identifying women at higher 
risk for inherited forms are very promising in terms of cost-
effectiveness. On the contrary, more high-quality studies are 
needed to prove the cost-effectiveness of BRCA genetic testing 
as an instrument of secondary prevention in affected women 
with predisposing gene mutation.
In any case, the price of BRCA1/2 testing is of paramount 
importance in determining the cost-effectiveness of BRCA1/2 
testing programs.44 If the cost of testing falls significantly, then 
all BRCA1/2 testing strategies analyzed in this review—perhaps 
including population-based screening—are likely to become 
highly cost-effective interventions.
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